|
Patient characteristics |
||
| 6 FEC 100 |
3 FEC/3D |
|
|
|
||
| Total number of patients (154) |
84 |
70 |
| Median age (range) |
43.5 (28–58) |
44 29–53) |
| Patients < 40 years (n = 39) |
18 (21.5 %) |
21 (30 %) |
| Patients ≥ 40 years (n = 115) |
66 (78 %) |
49 (70 %) (p = 0.08) |
| Hormone receptor status |
||
| Positive (ER and/or PR) |
61 (72.6 %) |
53 (75.9 %) |
| Negative (ER and PR) |
23 (27.4 %) |
17 (24.1 %) |
| ER positive |
60 (71.4 %) |
52 (74.2 %) |
| ER negative |
24 (28.5 %) |
18 (25.7 %) |
| PR positive |
50 (59.5 %) |
44 (62.8 %) |
| PR negative |
34 (40.4 %) |
26 (37.1 %) |
|
|
||
| Median tumor size (range) |
||
| Tumor grade |
||
| I |
8 (9.5 %) |
6 (8.6 %) |
| II |
34 (40.5 %) |
30 (42.8 %) |
| III |
42 (50 %) |
34 (48.6 %) |
| Number of metastatic lymph nodes |
||
| < 4 |
66 (78.6 %) |
53 (75.9 %) |
| ≥ 4 |
18 (21.4 %) |
17 (24.1 %) |
| Tumor size |
||
| T1 |
25 (29.7 %) |
21 (30 %) |
| T2 |
50 (59.5 %) |
42 (60 %) |
| T3 |
9 (10.8 %) |
7 (10 %) |
|
ER: estrogen receptor; PR: progesterone receptor (p-value never < 0.05) | ||
Berliere et al. BMC Cancer 2008 8:56 doi:10.1186/1471-2407-8-56 |
||